Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more
Cytogen Inc (217330) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.023x
Based on the latest financial reports, Cytogen Inc (217330) has a cash flow conversion efficiency ratio of -0.023x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-940.30 Million) by net assets (₩41.66 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cytogen Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Cytogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cytogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GEA Grenobl. Elect.
PA:GEA
|
0.134x |
|
Development Advance Solution Co Ltd
KO:058730
|
0.128x |
|
International Gas Product Shipping JSC
VN:GSP
|
N/A |
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
0.102x |
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
|
1.726x |
|
Singha Estate Public Company Limited
BK:S
|
0.022x |
|
ICBC Turkey Bank AS
IS:ICBCT
|
1.650x |
|
DAEMO Engineering Co. Ltd
KQ:317850
|
0.038x |
Annual Cash Flow Conversion Efficiency for Cytogen Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Cytogen Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩48.58 Billion | ₩-9.53 Billion | -0.196x | -37.81% |
| 2023-12-31 | ₩53.36 Billion | ₩-7.59 Billion | -0.142x | +87.38% |
| 2022-12-31 | ₩5.66 Billion | ₩-6.38 Billion | -1.128x | -396.17% |
| 2021-12-31 | ₩23.01 Billion | ₩-5.23 Billion | -0.227x | +6.68% |
| 2020-12-31 | ₩18.34 Billion | ₩-4.47 Billion | -0.244x | -29.58% |
| 2019-12-31 | ₩17.92 Billion | ₩-3.37 Billion | -0.188x | -49.56% |
| 2018-12-31 | ₩22.04 Billion | ₩-2.77 Billion | -0.126x | +72.70% |
| 2017-12-31 | ₩4.73 Billion | ₩-2.18 Billion | -0.460x | +90.73% |
| 2016-12-31 | ₩475.51 Million | ₩-2.36 Billion | -4.969x | -551.88% |
| 2015-12-31 | ₩2.66 Billion | ₩-2.03 Billion | -0.762x | +64.00% |
| 2014-12-31 | ₩484.59 Million | ₩-1.03 Billion | -2.118x | -- |